421 related articles for article (PubMed ID: 15389617)
1. Pharmacotherapy for obsessive-compulsive disorder.
Dougherty DD; Rauch SL; Jenike MA
J Clin Psychol; 2004 Nov; 60(11):1195-202. PubMed ID: 15389617
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
[TBL] [Abstract][Full Text] [Related]
3. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological management of obsessive-compulsive disorder: a review for clinicians.
McDonough M; Kennedy N
Harv Rev Psychiatry; 2002; 10(3):127-37. PubMed ID: 12023928
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapies in the management of obsessive-compulsive disorder.
Blier P; Habib R; Flament MF
Can J Psychiatry; 2006 Jun; 51(7):417-30. PubMed ID: 16838823
[TBL] [Abstract][Full Text] [Related]
6. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
Nakamae T
Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
[TBL] [Abstract][Full Text] [Related]
8. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder.
Pallanti S; Hollander E; Goodman WK
J Clin Psychiatry; 2004; 65 Suppl 14():6-10. PubMed ID: 15554782
[TBL] [Abstract][Full Text] [Related]
9. The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap.
Szechtman H; Harvey BH; Woody EZ; Hoffman KL
Pharmacol Rev; 2020 Jan; 72(1):80-151. PubMed ID: 31826934
[TBL] [Abstract][Full Text] [Related]
10. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.
Bogan AM; Koran LM; Chuong HW; Vapnik T; Bystritsky A
J Clin Psychiatry; 2005 Jan; 66(1):73-9. PubMed ID: 15669891
[TBL] [Abstract][Full Text] [Related]
11. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762].
Carey PD; Vythilingum B; Seedat S; Muller JE; van Ameringen M; Stein DJ
BMC Psychiatry; 2005 Jan; 5():5. PubMed ID: 15667657
[TBL] [Abstract][Full Text] [Related]
12. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapeutic Strategies and New Targets in OCD.
Pittenger C
Curr Top Behav Neurosci; 2021; 49():331-384. PubMed ID: 33751503
[TBL] [Abstract][Full Text] [Related]
15. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
Saxena S; Wang D; Bystritsky A; Baxter LR
J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
[TBL] [Abstract][Full Text] [Related]
16. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
Ammar G; Naja WJ; Pelissolo A
Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.
Pessina E; Albert U; Bogetto F; Maina G
Int Clin Psychopharmacol; 2009 Sep; 24(5):265-9. PubMed ID: 19629012
[TBL] [Abstract][Full Text] [Related]
18. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
[TBL] [Abstract][Full Text] [Related]
19. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
Mohr N; Vythilingum B; Emsley RA; Stein DJ
Int Clin Psychopharmacol; 2002 Jan; 17(1):37-40. PubMed ID: 11800505
[TBL] [Abstract][Full Text] [Related]
20. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]